“Botanicals Market Report is set to have rapid growth due to increased consumer awareness for preventive healthcare, aging population, increasing prevalence of chronic problems, assurance of no side effects at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Botanicals Market Forecast 2019-2029: By Intervention (Ayurveda, Naturopathy & Homeopathy), By Distribution Channel (Direct Sales, E-commerce), By Region And Segment Forecasts.

For centuries, natural products, extracts and natural products have been used as a form of treatment for various acute and chronic disorders. Over time, various improvements have been made to natural products that have led to a correct dosage and properties from raw forms and are now classified under the name of botanical products / herbal supplements / natural supplements.

Botanical products on the market are available in various forms including oils, tablets, herbs, powders. Even in this advanced age, botanical products are widely used by almost all population groups ranging from newborns, youngsters and adults. People are adopting botanical products for almost all types of ailments such as dietary supplements for chronic pain and injury treatment. Greater consumer awareness for preventive health care together with an aging population, an increase in the prevalence of chronic problems such as cardiovascular disease, diabetes, obesity, and a greater belief that there are no side effects unlike modern medicine were the main ones factors that have contributed to the growth of the market.

Leading companies featured in the report include Dabur, Ricola, Herbalife, Himalaya, Omega Protein Corp., Amway, Bayer AG, Naturalife Asia Co., Bio-Botanica Inc. and Nature's Bounty Co.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

Read

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

Read

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

Read

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever